SK15262002A3 - Peptid modulujúci trombopoetínový receptor - Google Patents

Peptid modulujúci trombopoetínový receptor Download PDF

Info

Publication number
SK15262002A3
SK15262002A3 SK1526-2002A SK15262002A SK15262002A3 SK 15262002 A3 SK15262002 A3 SK 15262002A3 SK 15262002 A SK15262002 A SK 15262002A SK 15262002 A3 SK15262002 A3 SK 15262002A3
Authority
SK
Slovakia
Prior art keywords
tpo
day
oligopeptide
oligopeptides
cell
Prior art date
Application number
SK1526-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Tatjana Narada
Lennart Olson
Original Assignee
Pliva, Farmaceutska Industrija, Dioni�Ko Dru�Tvo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pliva, Farmaceutska Industrija, Dioni�Ko Dru�Tvo filed Critical Pliva, Farmaceutska Industrija, Dioni�Ko Dru�Tvo
Publication of SK15262002A3 publication Critical patent/SK15262002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK1526-2002A 2000-04-25 2001-04-23 Peptid modulujúci trombopoetínový receptor SK15262002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00108075A EP1149906A1 (en) 2000-04-25 2000-04-25 Thrombopoietin receptor modulating peptide
PCT/EP2001/004553 WO2001080873A2 (en) 2000-04-25 2001-04-23 Thrombopoietin receptor modulating peptide

Publications (1)

Publication Number Publication Date
SK15262002A3 true SK15262002A3 (sk) 2003-05-02

Family

ID=8168467

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1526-2002A SK15262002A3 (sk) 2000-04-25 2001-04-23 Peptid modulujúci trombopoetínový receptor

Country Status (24)

Country Link
US (1) US20030181659A1 (ko)
EP (2) EP1149906A1 (ko)
JP (1) JP2003530867A (ko)
KR (1) KR20030009450A (ko)
CN (1) CN1426467A (ko)
AR (1) AR030278A1 (ko)
AU (2) AU2001267366B9 (ko)
BG (1) BG107214A (ko)
BR (1) BR0110383A (ko)
CA (1) CA2407167A1 (ko)
CZ (1) CZ20023517A3 (ko)
EA (1) EA006423B1 (ko)
EE (1) EE200200610A (ko)
GE (1) GEP20063763B (ko)
HU (1) HUP0300559A3 (ko)
IL (1) IL152204A0 (ko)
IS (1) IS6582A (ko)
MX (1) MXPA02010458A (ko)
NO (1) NO20025114L (ko)
PL (1) PL358304A1 (ko)
SK (1) SK15262002A3 (ko)
WO (1) WO2001080873A2 (ko)
YU (1) YU79202A (ko)
ZA (1) ZA200208662B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002359362A1 (en) * 2001-11-07 2003-05-19 Millennium Pharmaceuticals, Inc. Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
MXPA05003057A (es) * 2002-09-18 2006-04-18 Johnson & Johnson Metodos para aumentar la produccion de celulas madre hematopoyeticas y plaquetas.
BR0317237A (pt) 2002-12-11 2005-11-01 Ferrosan As Dispositivo para amostragem ou coleta, kit, usos de um dispositivo e de um kit, e, métodos para diminuir a quantidade de um marcador em uma área de amostra, para amostrar de modo qualitativo ou quantitativo uma área quanto ao teor de um marcador e para cultivar microorganismos ou células de mamìferos coletados
MXPA05012315A (es) * 2003-05-12 2006-04-18 Affymax Inc Compuestos poli(etilenglicol) modificados novedosos y usos de los mismos.
MXPA05012314A (es) * 2003-05-12 2006-04-18 Affymax Inc Radical separador para peptido modificado con polietilenglicol.
JP2005187435A (ja) * 2003-12-26 2005-07-14 Otsuka Chemical Co Ltd 血小板産生促進組成物
EP1713521B1 (en) 2004-01-30 2010-07-28 Ferrosan A/S Haemostatic sprays and compositions
AU2005262070B2 (en) 2004-07-09 2011-01-27 Ferrosan Medical Devices A/S Haemostatic composition comprising hyaluronic acid
KR101367658B1 (ko) * 2006-01-31 2014-02-25 쥬리디컬 파운데이션 더 케모-세로-쎄라퓨틱 리서치 인스티튜트 파종성 혈관내 응고증후군의 병태를 파악하는 방법
JP5569398B2 (ja) 2008-02-29 2014-08-13 フェッローサン メディカル ディバイス エー／エス 止血および／または創傷治癒を促進するための装置
WO2012157586A1 (ja) * 2011-05-13 2012-11-22 国立大学法人東京大学 多核化巨核球細胞、及び血小板の製造方法
RU2657955C2 (ru) 2012-03-06 2018-06-18 Ферросан Медикал Дивайсиз А/С Контейнер под давлением, содержащий гемостатическую пасту
CA2874290C (en) 2012-06-12 2020-02-25 Ferrosan Medical Devices A/S Dry haemostatic composition
WO2014202760A2 (en) 2013-06-21 2014-12-24 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
EP3079731B1 (en) 2013-12-11 2018-08-08 Ferrosan Medical Devices A/S Dry composition comprising an extrusion enhancer
CA2960309A1 (en) 2014-10-13 2016-04-21 Ferrosan Medical Devices A/S Dry composition for use in haemostasis and wound healing
RU2705905C2 (ru) 2014-12-24 2019-11-12 Ферросан Медикал Дивайсиз А/С Шприц для удерживания и смешивания первого и второго веществ
BR112017027695A2 (pt) 2015-07-03 2018-09-04 Ferrosan Medical Devices As seringa para retenção e mistura de primeira e segunda substâncias
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5498599A (en) * 1994-01-21 1996-03-12 Amgen Inc. Methods for stimulating platelet production
YU34196A (sh) * 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US6342220B1 (en) * 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU2783099A (en) * 1998-02-24 1999-09-06 Receptron, Inc. Receptor derived peptides as modulators of receptor activity

Also Published As

Publication number Publication date
EA200201138A1 (ru) 2003-06-26
CA2407167A1 (en) 2001-11-01
AR030278A1 (es) 2003-08-20
HUP0300559A3 (en) 2005-09-28
AU6736601A (en) 2001-11-07
KR20030009450A (ko) 2003-01-29
PL358304A1 (en) 2004-08-09
EP1278849A2 (en) 2003-01-29
BG107214A (bg) 2003-11-28
NO20025114L (no) 2002-12-18
NO20025114D0 (no) 2002-10-24
US20030181659A1 (en) 2003-09-25
EE200200610A (et) 2004-08-16
HUP0300559A2 (hu) 2003-06-28
EA006423B1 (ru) 2005-12-29
IS6582A (is) 2002-10-14
CN1426467A (zh) 2003-06-25
BR0110383A (pt) 2003-01-21
MXPA02010458A (es) 2003-06-06
WO2001080873A2 (en) 2001-11-01
ZA200208662B (en) 2003-10-27
YU79202A (sh) 2006-01-16
WO2001080873A3 (en) 2002-01-31
AU2001267366B2 (en) 2005-06-30
AU2001267366B9 (en) 2005-07-14
CZ20023517A3 (cs) 2003-10-15
EP1149906A1 (en) 2001-10-31
GEP20063763B (en) 2006-03-10
JP2003530867A (ja) 2003-10-21
IL152204A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
AU2001267366B2 (en) Thrombopoietin receptor modulating peptide
JP5823954B2 (ja) Ｆｇｆ２１変異体及びその使用
JP2019058182A (ja) 制御性ｔ細胞の増殖のためのインターロイキン−２ムテイン
AU2001267366A1 (en) Thrombopoietin receptor modulating peptide
JP6041843B2 (ja) ＩＬ−１ｒａの凝集を低下させる方法
WO2010070047A1 (en) Soluble polypeptides for use in treating autoimmune and inflammatory disorders
JP2012525847A (ja) Ｆｇｆ２１変異体およびその使用
EA010371B1 (ru) Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов
JP2014531432A (ja) 薬物動態特性の改善されたコンプスタチンアナログ
AU2005249373A1 (en) Use of GPCR54 ligands for the treatment of infertility
EP3973981A1 (en) Huwentoxin-iv variants and methods of use
KR20130132429A (ko) 모에신 조절제 및 그의 용도
JP2018522547A (ja) Ｉｌ−３７バリアント
US10414808B2 (en) Huwentoxin-IV variants and methods of use
CA2516364A1 (en) Method of modulation
WO2020112565A1 (en) Antagonists of mitofusion 1 and beta ii pkc association for treating heart failure
TWI238191B (en) IL-17 like molecules and uses thereof
US8841253B2 (en) Viral/bacterial toxin polypeptides and methods of using same
US20070270339A1 (en) Use of GPCR54 Ligands for the Treatment of Infertility
US8945575B2 (en) Treatment of IgE-mediated disease
WO2023108666A1 (zh) 一类靶向covid-19病毒s蛋白的超高亲和力小蛋白及用途
EP4306545A1 (en) Fusion protein of tnfr2 and april baff receptor
US20090054330A1 (en) Novel Therapeutic Use of Viral Inflammation Modulatory Protein in Blocking Xenograft Rejection